Investigation of Blood Count-Based Inflammatory Biomarkers as Predictors of Response to Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps
Open Access
- 25 October 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (11) , 1370
Abstract
Background/Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often resistant to standard treatments. Dupilumab, a monoclonal antibody targeting the IL-4α receptor, has shown efficacy in CRSwNP, but a significant subset of patients do not respond to this therapy. This study aims to investigate pretreatment complete blood count (CBC)-based inflammatory biomarkers as predictors of response to dupilumab in patients with CRSwNP. Methods: This mono-centric, retrospective, single-arm longitudinal cohort study included 80 patients with uncontrolled CRSwNP who received dupilumab treatment at the Medical University of Graz. Patients were classified into responder and non-responder groups based on a reduction of >1 in nasal polyp score (NPS) and a sinonasal outcome test-22 (SNOT-22) score p = 0.027), suggesting that higher eosinophil levels may predict higher NPS reduction in dupilumab treatment. However, no significant associations were observed between NLR, PLR, and systemic inflammation indices with treatment outcomes. Conclusions: Pretreatment eosinophil count may serve as a potential biomarker for predicting nasal polyp reduction in dupilumab treatment of CRSwNP. Other CBC-based inflammatory markers did not show significant predictive value. Further prospective studies are needed to validate these findings and explore additional, reliable biomarkers to optimize treatment outcomes for CRSwNP patients.Keywords
This publication has 51 references indexed in Scilit:
- Patterns of recurrence in patients with CRSwNP who underwent complete FESSEuropean Archives of Oto-Rhino-Laryngology, 2024
- Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literatureEuropean Archives of Oto-Rhino-Laryngology, 2024
- The value of biomarkers in the therapy of CRSwNP with biologicals—a long-term follow-up of dupilumab therapyEuropean Archives of Oto-Rhino-Laryngology, 2024
- Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary reportEuropean Archives of Oto-Rhino-Laryngology, 2023
- A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposisInternational Forum of Allergy & Rhinology, 2022
- Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trialsInternational Forum of Allergy & Rhinology, 2022
- Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polypsInternational Forum of Allergy & Rhinology, 2021
- Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome ThresholdsThe Laryngoscope, 2021
- Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposisThe Laryngoscope, 2016
- A novel predictive marker for the recurrence of nasal polyposis following endoscopic sinus surgeryEuropean Archives of Oto-Rhino-Laryngology, 2015